Trial Profile
A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-cell Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 28 Dec 2021
Price :
$35
*
At a glance
- Drugs Sapacitabine (Primary)
- Indications Cutaneous T-cell lymphoma
- Focus Therapeutic Use
- Sponsors Cyclacel Pharmaceuticals
- 07 Nov 2011 Planned End Date changed from 1 Jun 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 07 Nov 2011 Planned End Date changed from 1 Jun 2010 to 1 Mar 2012 as reported by ClinicalTrials.gov.
- 27 Oct 2009 Planned end date changed from 1 Oct 2008 to 1 Jun 2010 as reported by ClinicalTrials.gov.